Syncom Formulations (India) Limited (BOM: 524470)

Market Cap	24.29B
Revenue (ttm)	2.91B
Net Income (ttm)	285.50M
Shares Out	940.00M
EPS (ttm)	0.38
PE Ratio	68.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,766,376
Open	27.51
Previous Close	26.77
Day's Range	25.37 - 27.94
52-Week Range	7.66 - 27.94
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Syncom Formulations (India)

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It also provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 555
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524470

Financial Performance

In 2023, Syncom Formulations (India)'s revenue was 2.63 billion, an increase of 17.45% compared to the previous year's 2.24 billion. Earnings were 253.14 million, an increase of 26.13%.